Related Experiment Video
Updated: Aug 29, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
Dendritic cells in cancer immunotherapy - a short review
Kamila Wojas1, Jacek Tabarkiewicz, Jacek Roliński
1Department of Clinical Immunology, Medical University, Lublin, Poland. kamilawojas@poczta@onet.pl
Abstract:
Dendritic cells (DCs) are rare leukocytes that are uniquely potent in their recent application to therapeutic cancer vaccines. Isolated DCs loaded with tumour antigen ex vivo and administered as a cellular vaccine have been found to induce protective and therapeutic anti-tumour immunity. In the present report we describe the most common methods of culturing DCs and delivering tumour antigens and we summarise clinical trials of cancer immunotherapy using DCs-based vaccines.
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
The Tumor Microenvironment
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...

